Respiratorius Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Respiratorius
Access all reports
Respiratorius AB develops drug candidates with the goal of launching or out-licensing drugs for the treatment of aggressive lymphoma (cancer). Respiratorius is developing a new drug as a pretreatment to enhance the effects of the standard treatment currently used for the treatment of diffuse large B-cell lymphoma, the most common type of aggressive lymphoma.
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden